Imagine a condition so stealthy that it silently weakens bones over decades, only revealing itself through a devastating fracture that could rob a person of independence or even life—yet it’s rarely discussed in relation to half the population. Osteoporosis, long branded as a women’s health
Short introductionToday, we’re thrilled to sit down with Ivan Kairatov, a seasoned biopharma expert with extensive experience in research, development, and innovation within the industry. With a keen eye on the evolving landscape of obesity treatments, Ivan offers unique insights into the
I'm thrilled to sit down with Ivan Kairatov, a biopharma expert with extensive experience in research and development, particularly in the realm of cutting-edge technologies and innovations in the industry. Today, we’re diving into the groundbreaking world of gene therapy for hearing loss, focusing
What happens when the tools used to fight one of the deadliest cancers fail to tell the full story, and how can a new approach change the game? Glioblastoma, an aggressive brain cancer with a survival rate of less than 15 months for most patients, has long evaded effective treatment, but a
Imagine a world where life-saving medical research grinds to a halt, not because of a lack of expertise or innovation, but due to political disputes far removed from the lab. This scenario is unfolding across the University of California (UC) system, where federal funding freezes initiated by the
In the realm of clinical research, the conclusion of a trial often feels like crossing a finish line, with key milestones such as database lock, the final monitoring visit, or the last patient out signaling closure for sponsors and contract research organizations (CROs). However, for the
